WO2010002217A3 - 페하 민감성 금속 나노 입자 및 이의 제조 방법 - Google Patents

페하 민감성 금속 나노 입자 및 이의 제조 방법 Download PDF

Info

Publication number
WO2010002217A3
WO2010002217A3 PCT/KR2009/003640 KR2009003640W WO2010002217A3 WO 2010002217 A3 WO2010002217 A3 WO 2010002217A3 KR 2009003640 W KR2009003640 W KR 2009003640W WO 2010002217 A3 WO2010002217 A3 WO 2010002217A3
Authority
WO
WIPO (PCT)
Prior art keywords
metal nanoparticle
sensitive
sensitive metal
preparation
particle
Prior art date
Application number
PCT/KR2009/003640
Other languages
English (en)
French (fr)
Other versions
WO2010002217A2 (ko
Inventor
김성지
정상화
정효균
남주택
원나연
Original Assignee
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포항공과대학교 산학협력단 filed Critical 포항공과대학교 산학협력단
Priority to JP2011516156A priority Critical patent/JP5577329B2/ja
Priority to EP09773753.0A priority patent/EP2308799B1/en
Priority to CN200980125951.9A priority patent/CN102083741B/zh
Priority to US13/002,476 priority patent/US9616122B2/en
Publication of WO2010002217A2 publication Critical patent/WO2010002217A2/ko
Publication of WO2010002217A3 publication Critical patent/WO2010002217A3/ko
Priority to US15/438,698 priority patent/US20170226474A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02—Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0285—Nanoscale sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 pH 민감성 입자 및 이의 제조 방법 및 용도에 관한 것으로서, 보다 상세하게는 pH 민감성 금속 나노 입자와 이의 제조 방법 및 광열 치료를 통한 세포사멸을 통한 치료용 용도를 제공하는 것이다. 본 발명에 따른 pH 민감성 금속 나노입자는 금속 나노입자에 pH에 따라 전하가 변하는 pH 민감성 리간드 화합물이 형성되어 있어, 암세포와 같은 비정상적 pH 환경을 가지는 세포에서 응집될 수 있다. 본 발명에 따른 pH 민감성 금속 나노입자는 응집 후 광열 과정을 통해서 세포의 사멸을 유도할 수 있어, 암세포 치료와 같이 세포의 사멸을 통한 치료가 가능하게 된다.
PCT/KR2009/003640 2008-07-03 2009-07-03 페하 민감성 금속 나노 입자 및 이의 제조 방법 WO2010002217A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2011516156A JP5577329B2 (ja) 2008-07-03 2009-07-03 ｐＨ感受性金属ナノ粒子およびその製造方法
EP09773753.0A EP2308799B1 (en) 2008-07-03 2009-07-03 Ph sensitive metal nanoparticle and preparation method
CN200980125951.9A CN102083741B (zh) 2008-07-03 2009-07-03 pH敏感性金属纳米粒子及其制造方法
US13/002,476 US9616122B2 (en) 2008-07-03 2009-07-03 PH sensitive metal nanoparticle and preparation method
US15/438,698 US20170226474A1 (en) 2008-07-03 2017-02-21 Ph sensitive metal and nanoparticle and preparation method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080064270A KR101014246B1 (ko) 2008-07-03 2008-07-03 페하 민감성 금속 나노 입자 및 이의 제조 방법.
KR10-2008-0064270 2008-07-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/002,476 A-371-Of-International US9616122B2 (en) 2008-07-03 2009-07-03 PH sensitive metal nanoparticle and preparation method
US15/438,698 Division US20170226474A1 (en) 2008-07-03 2017-02-21 Ph sensitive metal and nanoparticle and preparation method

Publications (2)

Publication Number Publication Date
WO2010002217A2 WO2010002217A2 (ko) 2010-01-07
WO2010002217A3 true WO2010002217A3 (ko) 2010-06-24

Family

ID=41466491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003640 WO2010002217A2 (ko) 2008-07-03 2009-07-03 페하 민감성 금속 나노 입자 및 이의 제조 방법

Country Status (6)

Country Link
US (2) US9616122B2 (ko)
EP (1) EP2308799B1 (ko)
JP (1) JP5577329B2 (ko)
KR (1) KR101014246B1 (ko)
CN (1) CN102083741B (ko)
WO (1) WO2010002217A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
KR101276693B1 (ko) * 2010-10-29 2013-06-19 포항공과대학교 산학협력단 양쪽성 이온을 가진 나노입자 표면 개질용 표면 분자체의 합성과 그 응용
KR101368179B1 (ko) * 2010-11-12 2014-03-03 포항공과대학교 산학협력단 강한 전하를 가지는 나노입자 표면 분자체와 이를 이용한 생접합 및 층상 자기조립 방법
US10012653B2 (en) * 2011-06-15 2018-07-03 Board Of Regents, The University Of Texas System Nanoparticles for targeting acid tumor microenvironments
US20130189367A1 (en) * 2011-07-29 2013-07-25 University Of Washington Through Its Center For Commercialization Nanovectors for targeted gene silencing and cytotoxic effect in cancer cells
CN102989016A (zh) * 2012-11-05 2013-03-27 浙江大学 一种具有pH敏感性的纳米微粒材料及其制备方法
KR20140092430A (ko) * 2012-12-26 2014-07-24 삼성전자주식회사 나노입자 조립체, 이의 제조방법 및 이를 포함하는 활성물질 전달 복합체
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US9874554B1 (en) 2014-07-16 2018-01-23 Verily Life Sciences Llc Aptamer-based in vivo diagnostic system
CN104667301B (zh) * 2015-02-12 2017-08-22 东北师范大学 一种单分散核壳结构AuNCs‑A@CaP纳米粒子的制备方法及其应用
EP3426300A4 (en) 2016-03-08 2019-10-30 National Medical Center Children's FUNCTIONALIZED PRUSSE BLUE NANOPARTICLES, COMBINATORY NANO-IMMUNOTHERAPY BASED ON PRUSSIAN BLUE NANOPARTICLES AND THEIR APPLICATIONS
CN107941778A (zh) * 2017-10-11 2018-04-20 南方医科大学南方医院 一种用于检测体液pH的传感器及其制备和应用方法
CN111514308B (zh) * 2020-03-10 2023-02-17 西南民族大学 pH诱导电荷翻转型抗菌金纳米棒及其制备方法和应用
CN113899732B (zh) * 2021-09-30 2023-09-22 航天科工(长沙)新材料研究院有限公司 pH值敏感型配体修饰纳米金及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340527C (en) * 1988-05-31 1999-05-04 Lidia Vallarino Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
DE60115667T2 (de) 2000-09-05 2006-08-24 Centelion Säureempfindliche verbindungen, deren herstellung und verwendungen
GB0321937D0 (en) * 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
US7601331B2 (en) * 2004-11-10 2009-10-13 National University Of Singapore NIR-sensitive nanoparticle
KR100645597B1 (ko) 2005-03-24 2006-11-14 이지로보틱스 주식회사 로봇 리모컨 서비스 방법 및 장치
KR100713745B1 (ko) 2006-02-27 2007-05-07 연세대학교 산학협력단 상전이 리간드로 코팅된 수용성 자성 또는 금속 산화물나노입자 및 이의 제조방법
KR20080008668A (ko) * 2006-07-20 2008-01-24 재단법인서울대학교산학협력재단 자성체 나노입자를 이용하여 단백질을 선택적으로 결합,분리 또는 정제하는 방법
KR100802080B1 (ko) 2007-03-28 2008-02-11 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENG, Z. ET AL.: "A General Strategy Toward pH-Controlled Aggregation-Dispersion of Gold Nanoparticles and Single-Walled Carbon Nanotubes", SMALL, vol. 4, no. 3, 13 February 2008 (2008-02-13), pages 326 - 329, XP008141592 *
GUPTA, V. K. ET AL.: "Reversible aggregation of gold nanoparticles induced by pH dependent conformational transitions of a self-assembled polypeptide", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 316, 2007, pages 977 - 983, XP022328699 *
KRISHNAN, S. ET AL.: "Modulation of in Vivo Tumor Radiation Response via Gold Nanoshell-Mediated Vascular-Focused Hyperthermia: Characterizing an Integrated Antihypoxic and Localized Vascular Disrupting Targeting Strategy", NANO LETTERS, vol. 8, no. 5, 16 April 2008 (2008-04-16), pages 1492 - 1500, XP008141560 *
See also references of EP2308799A4 *
TENHU, H. ET AL.: "Gold Nanoparticles Protected with pH and Temperature- Sensitive Diblock Copolymer", LANGMUIR, vol. 23, 2007, pages 5352 - 5357, XP008141561 *
ZHANG, W. ET AL.: "Formation of Gold@Polymer Core-Shell Particles and Gold Particle Clusters on a Template of Thermoresponsive and pH-Responsive Coordination Triblock Copolymer", LANGMUIR, vol. 22, 2006, pages 9393 - 9396, XP008141562 *

Also Published As

Publication number Publication date
EP2308799B1 (en) 2017-11-08
KR20100004220A (ko) 2010-01-13
US9616122B2 (en) 2017-04-11
US20170226474A1 (en) 2017-08-10
JP2011526883A (ja) 2011-10-20
WO2010002217A2 (ko) 2010-01-07
US20110269170A1 (en) 2011-11-03
CN102083741B (zh) 2015-11-25
KR101014246B1 (ko) 2011-02-16
JP5577329B2 (ja) 2014-08-20
EP2308799A4 (en) 2014-12-17
EP2308799A2 (en) 2011-04-13
CN102083741A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
WO2010002217A3 (ko) 페하 민감성 금속 나노 입자 및 이의 제조 방법
WO2010114874A3 (en) Conductive compositions containing blended alloy fillers
WO2011153553A3 (en) Methods and compositions for kinase inhibition
WO2011129549A3 (ko) Ph 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
WO2015006498A3 (en) Therapeutic uses of genome editing with crispr/cas systems
GB2460380A (en) Stabilized lithium metal powder for li-ion application, composition and process
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2012081904A3 (en) Nano wire and method for manufacturing the same
WO2012138379A3 (en) Multifunctional chelator-free radioactive nanoparticles for imaging and therapy
WO2010002773A3 (en) Method for in situ formation of metal nanoclusters within a porous substrate field
WO2009012109A3 (en) Cyanine-containing compounds for cancer imaging and treatment
WO2012034082A3 (en) A method of treating soil and a method of sequestering heavy metals in soil
EP2620455A4 (en) METHOD FOR PRODUCING ACRYLIC-CLOSED MODIFIED POLYBUTADIA OR ACRYLIC-CLOSED HYDROGENATED POLYBUTADIENE AND COMPOSITION THEREWITH
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
WO2010065329A3 (en) Nanoparticles for cancer treatment
WO2012037299A3 (en) Fatty acid synthase inhibitors
WO2012052479A3 (en) Brimonidine gel compositions and methods of use
WO2010074539A3 (ko) 고온의 ａｃ 자기 유도 발열을 보이는 가공된 초 상자성 마그네슘 도핑된 페라이트 나노입자의 제조방법 및 그 방법에 의하여 제조된 가공된 초상자성 마그네슘 도핑된 페라이트 나노입자
WO2012019000A3 (en) Biomarkers for the identification monitoring and treatment of ovarian cancer
WO2019083323A3 (ko) 자성 나노 구조체 및 그 제조방법
IN2012DE00893A (ko)
NZ708654A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2008067079A3 (en) Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles
WO2014031759A3 (en) Inhibitors of crl4 ubiquitin ligase and uses thereof
PH12015500680B1 (en) Method for preventing/controlling rice diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980125951.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09773753

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011516156

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009773753

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009773753

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13002476

Country of ref document: US